Compare Fabrinet (FN) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fabrinet vs Merck & Co., Inc. — how do they compare? Fabrinet trades at $500 (market cap $17.46B), while Merck & Co., Inc. trades at $142.58 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 20.1× Fabrinet's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Fabrinet pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fabrinet for 30 Days and Merck & Co., Inc. for 98 Days on average.
| FN | MRK | |
|---|---|---|
Market Cap | $17.46B | $351.28B |
Volume | 1,199,886 | 7,969,665 |
Sector | Technology | Health |
52-Week High | $746.47 | $156.43 |
52-Week Low | $361.94 | $82.49 |
Typical Hold Time | 30 Days | 98 Days |
Enterprise Value | $16.59B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fabrinet (FN) trades at $497.99, up 1.81% today, with a bullish technical signal and strong analyst support. The stock shows robust fundamentals, including a 45% year-over-year revenue growth in Q4 2026 and consistent earnings beats, driven by surging AI data center demand. Valuation ratios like P/E of 37.34 and P/S of 3.81 reflect high growth expectations. Recent news highlights capacity expansion and AI-driven growth, though high RSI levels suggest potential overbought conditions.
The outlook for FN is positive, with a consensus price target of $769.50 implying significant upside. Key opportunities include AI infrastructure demand and operational leverage, but risks involve customer concentration, margin pressure from high spending, and insider selling. Investors should weigh strong growth prospects against valuation and execution risks in a competitive sector.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fabrinet
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
